Virtu KCG Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Virtu KCG Holdings’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$471K	Sell	7,588 -16,438	-68%	-$990K	0.01%	1202
2017 Q1	$1.63M	Buy	+24,026	New	+$1.83M	0.05%	369
2016 Q1	–	Sell	-4,938	Closed	-$554K	–	3498
2015 Q4	$554K	Buy	+4,938	New	+$494K	0.01%	1420
2015 Q3	–	Sell	-7,140	Closed	-$731K	–	3727
2015 Q2	$731K	Buy	+7,140	New	+$554K	0.01%	1142

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Virtu KCG Holdings's RARE Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Ultragenyx Pharmaceutical (RARE) stake by 68% in Q2 2017, selling an estimated $990K and leaving 7,588 shares worth $471K. The position accounts for 0.01% of the portfolio, ranked #1202.

Virtu KCG Holdings first reported a position in RARE in Q2 2015 and has held it in 4 quarters since. The position peaked at $1.63M in Q1 2017. 159 funds tracked by Wall St. Rank hold RARE as of Q2 2017.

Virtu KCG Holdings held 7,588 shares of Ultragenyx Pharmaceutical worth $471K as of Q2 2017.
Virtu KCG Holdings sold 16,438 Ultragenyx Pharmaceutical shares in Q2 2017, an estimated $990K.
Ultragenyx Pharmaceutical made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1202 holding.
Virtu KCG Holdings first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 4 quarters since.
Virtu KCG Holdings's Ultragenyx Pharmaceutical position peaked at $1.63M in Q1 2017.
159 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.